Virion Therapeutics press releaseVirion Therapeutics reports broad and sustained anti-HBV immunity following a single VRON-0200 dose in the majority of chronically HBV-infected patients from its Phase 1b study at CROI 2026

Virion Therapeutics announced at CROI 2026 that a single intramuscular dose of VRON-0200, its novel, first-in-class, immunotherapy for HBV functional cure was able to “spark” and re-awaken durable HBV-specific immunity in the majority of chronically HBV-infected patients – with HBsAg declines that were sustained or deepened through Day 360. These data, presented as a late breaker presentation, also highlighted VRON-0200’s ongoing favorable safety and tolerability profile, and its rapid and profound synergy when combined with antigen lowering antiviral agents.

Aligos Therapeutics press releaseAligos Therapeutics presents positive data at CROI 2026

Aligos Therapeutics announced positive data from two presentations at CROI 2026. The pevifoscorvir sodium presentation highlighted the Phase 1 monotherapy study of pevifoscorvir sodium, a potent CAM-E under development for the treatment of chronic hepatitis B virus (HBV) infection. Additionally, the ALG-097558 presentation (ALG-097558: Potential best-in-class ritonavir-free small molecule pan-coronavirus protease inhibitor) showcased data from participants with hepatic and renal impairment.

Atea Pharmaceuticals press releaseAtea Pharmaceuticals presents preclinical results supporting first-in-class potential of AT-587 for treatment of hepatitis E virus at CROI 2026

Atea Pharmaceuticals announced at CROI 2026 in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490, exhibit promising antiviral profiles as potential first-in-class inhibitors for the treatment of hepatitis E virus infection, a positive-sense, single-stranded RNA virus that primarily infects liver cells.

— SEE ALSO: Contagion Live: Antiviral emerges as a highly potent, first-in-class candidate for hepatitis E